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 Highlights 
What is already known about the topic? 
 Decision making will almost always require expert opinion to fill gaps in the evidence due to an absence 
of, or impossibility of conducting, relevant prospective studies. 
 A structured expert elicitation process quantifying experts’ uncertainty in belief is axiomatically 
preferable to less formal approaches such as uninformed point estimates with arbitrarily wide 
credibility intervals to represent parameter uncertainty. 
 Previous decision models have used an arbitrary 10% annual probability (approximately 5.1% per six 
months) of progression from one melanoma disease stage to another, with wide credibility intervals. 
What does this paper add? 
 We successfully elicited and pooled the beliefs of a number of UK, Australia and New Zealand experts 
in melanoma regarding the probability of disease progression from 12 discrete melanoma disease 
stages.  The pooled distribution has been included in a decision analytic model estimating the cost-
effectiveness of melanoma screening. 
 The transition probabilities differ substantially from the previous arbitrary estimates and their 
credibility intervals represent a more appropriate characterisation of uncertainty.  
 Abstract 
Background: Expert elicitation is required to inform decision making where relevant ‘better quality’ data either 
do not exist or cannot be collected.  An example of this is to inform decisions as to whether to screen for 
melanoma.  A key input is the counterfactual, in this case the natural history of melanoma in patients who are 
undiagnosed and hence untreated. 
Objectives: To elicit expert opinion on the probability of disease progression in patients with melanoma that is 
undetected and hence untreated. 
Methods: Bespoke webinar-based expert elicitation protocol administered to 14 participants in the UK, Australia 
and New Zealand, comprising 12 multinomial questions on the probability of progression from one disease stage 
to another in the absence of treatment.  A modified Connor-Mosimann distribution was fitted to individual 
responses to each question.  Individual responses were pooled using a Monte Carlo simulation approach.  
Participants were asked to provide feedback on the process. 
Results: A pooled modified Connor-Mosimann distribution was successfully derived from participants’ 
responses.  Feedback from participants was generally positive with 86% willing to take part in such an exercise 
again.  However, only 57% of participants felt this was a valid approach to determine the risk of disease 
progression.  Qualitative feedback reflected some understanding of the need to rely on expert elicitation in the 
absence of ‘hard’ data.   
Conclusion: We successfully elicited and pooled the beliefs of experts in melanoma regarding the probability of 
disease progression in a format suitable for inclusion in a decision analytic model. 
Keywords: expert elicitation, decision modelling, melanoma 
  
 Introduction 
Evidence based medicine is defined as the “conscientious, explicit, and judicious use of current best evidence in 
making decisions about the care of individual patients… [which] means integrating individual clinical expertise 
with the best available external clinical evidence from systematic research”.1  These principles apply equally to 
population level decision making, such as whether a healthcare payer should provide reimbursement for a new 
drug, treatment pathway or screening programme. 
Decision analytic models are frequently used by agencies such as the National Institute for Health and Care 
Excellence (NICE) in England as a framework to structure all current best (i.e. relevant, quality-assessed) 
evidence to estimate the overall costs and consequences of alternative treatment strategies over an appropriate 
time horizon.2 3  A judgment is then made to decide whether the added benefit of a treatment exceeds its 
opportunity cost.  Evidence to populate a model is ideally obtained exclusively from good quality systematic 
reviews and meta-analyses of RCTs or other relevant study designs as appropriate.  However, due to data 
limitations, evidence is typically obtained from various sources including routine databases and observational 
studies.  Where no suitable prior data exist decision makers are required to rely on expert opinion to bridge the 
evidence gaps. 
Such an evidence gap is the natural history of undetected and hence untreated melanoma.   
The Melatools programme (www.melatools.org) is an NIHR-funded programme based in the UK to improve the 
early diagnosis of melanoma to reduce associated mortality and morbidity.  This includes investigation of the 
feasibility and cost-effectiveness of introducing a risk-based surveillance programme using a self-completed 
assessment tool.4   
To address this we developed a decision model to estimate the most cost-effective cut-offs for various 
intervention policies.5  However, a key component of this is the counterfactual, in other words, the natural 
history of untreated melanoma in the absence of medical intervention.  Good quality data exist on prognosis 
post diagnosis and subsequent treatment,6 but there are no data on untreated individuals.  Obtaining such data 
from a prospective study by withholding treatment from newly diagnosed patients would clearly be deeply 
unethical.  Therefore, the only way to estimate the probability of an undiagnosed and hence untreated patient 
progressing from one disease stage to another is to garner expert opinion. 
 In this paper, we apply a method to elicit multinomial probabilities from experts regarding their beliefs about 
the rate of progression from different melanoma disease stages (in situ disease to stage IV) to any other stage 
or death.  The primary purpose of the analysis was to use the resulting multinomial distributions in our decision 
model to predict the cost-effectiveness of a self-completed risk assessment tool and subsequent surveillance 
programme.  However, the distributions themselves are of interest as they represent a summary of expert 
opinion and belief.  
 Method 
Research Problem 
There are four main types of cutaneous melanoma (superficial spreading, lentigo maligna, acral lentiginous and 
nodular),7 which current guidelines categorise into nine stages of invasion.6  All but one are also described with 
a pre-invasive (in situ) phase; nodular melanoma is by definition invasive.  We wished to elicit expert opinion on 
the rate of progression from each stage to any other. We simplified a possible set of 39 questions into 12 by 
assuming that invasive disease would progress at the same rate irrespective of primary melanoma subtype; we 
allowed the rate of progression from in situ disease to vary by subtype (Table 1).  Each question is a multinomial 
problem: the quantities to be elicited are probabilities, but there are more than two outcomes.  For example, 
after a defined time period, a patient with Stage 1a disease may remain in Stage 1a, or progress to 1b or 2a and 
so forth.  The sum of the probabilities must equal one. 
Elicitation Protocol 
The protocol and associated materials are in Appendix 1.  The protocol was designed with the following 
constraints in mind: 
 We wished to elicit opinion from experts of more than one country.  We chose the UK, and Australia and 
New Zealand (hereafter ANZ) as areas of relatively high melanoma prevalence.  Arranging a single workshop 
event in the same place at the same time would be prohibitively expensive and extremely difficult to 
schedule.  Therefore, an online webinar approach that could be repeated to suit availability of participants 
was desired. 
 Due to demands on experts’ time, the webinar could not exceed two hours in length. 
Ethics 
Ethical approval was not required for this study.8  Invitation letters explained to participants that their responses 
would be anonymised, with the only details being their broad job title and country (UK or ANZ). 
Identification and recruitment of experts 
Inclusion criteria were that participants had to be located in the UK, Australia or New Zealand with an academic 
or clinical background in either dermatology, oncology, plastic surgery, or epidemiology, with a particular 
interest and expertise in melanoma.  A list of potential participants was identified by two of the investigators 
(FW & JE), based on known expertise and relevant publications in the field.  Participants were invited to take 
 part via email, and several sessions were scheduled to allow flexibility to maximise recruitment.  Participants 
were paid an honorarium of £200 / Aus$400 for their time.   
Background materials 
We circulated background materials to participants prior to the webinars, including confirmation of date and 
time, an explanation of the overall purpose of the exercise, a user guide explaining how responses would be 
recorded (on a specifically designed Microsoft Excel spreadsheet) and relevant background literature.  The only 
relevant literature identified was the current AJCC staging recommendations for melanoma, which includes 
survival curves by disease stage at diagnosis.6  
Pre-elicitation training 
Each webinar began with a 30-minute presentation introducing the concept of elicitation and example 
questions, followed by a live demonstration of how to use the Excel spreadsheet.  
Elicitation method 
Questions were asked in the format of “Imagine a cohort of 100 patients with Stage X undiagnosed and hence 
untreated disease.  After 6 months, the patients may be in any of the following stages:”.  At this point participants 
could select from a drop-down list any stage they think it is possible for patients of the cohort to be in.  They 
then ranked these in order of likelihood, from most likely to least likely (screenshot in Figure 1a).  Once 
participants were happy with their selections they clicked ‘Update chart’ which populated a chart with the 
selected stages, ordered from most to least likely (Figure 1b), with a default equal spread of probabilities.  Edits 
to the chart could be made by selecting cells in the table below the chart and either clicking increase/decrease 
or by simply entering an appropriate number.  The chart updated instantly providing visual feedback to the 
participant. 
Participants were asked to first adjust the medians according to their beliefs, working from least to most likely 
(right to left of the chart, or bottom to top of the table, in the example shown starting from Stage 3B, then 3A 
etc).  A restriction was placed that the medians had to sum to 100; the software would not permit participants 
to finalise their answer unless this was satisfied.  Once the participant was happy that the selected medians did 
indeed represent their median beliefs, the lower and upper 95% credibility bounds were set for each stage, again 
working from right to left of the chart.  There was no restriction on the sum of the lower and upper bounds: 
participants could set them such that the interval contained within them represented the strength of their belief 
 about plausible values.  As before the chart updated immediately allowing the participant to visualise his/her 
responses.  Once happy, the participant clicked ‘submit’.  The responses were stored and timestamped and the 
spreadsheet automatically moved on to the next question. 
The webinar was designed such that it could be repeated with relative ease to accommodate availability of 
participants.  The facilitator (EW) would remain online whilst they completed the exercise to attend to any 
problems.  This also served to ensure participants completed the exercise at the allocated time and not rushed 
in their own time.  The timestamp on responses allowed monitoring of the length of time spent on each question. 
Fitting distributions to elicited data 
A modified Connor-Mosimann distribution9-11 (a generalisation of the Dirichlet distribution) was fitted to the 
elicited median and 95% credibility intervals for all dimensions for each participant.  These summary 
distributions were then sampled from many times (Monte Carlo simulation).  The empirical median and upper 
and lower 95% credibility bounds (ie. 2.5th, 50th and 97.5th centiles) were then calculated from the samples and 
a modified Conor-Mosimann distribution fitted to these overall figures, representing an aggregate of the 
individual participants’ beliefs.  This was conducted at a national level (UK and ANZ), and for all participants 
together.  Distributions were fitted using R.12  A copy of the code is available on request from the corresponding 
author. 
Piloting 
The protocol was piloted amongst Melatools steering committee members on three separate occasions, 
resulting in several modifications to the initial plans.  These related to the (1) specification and ordering of 
questions, (2) length of the webinar, and (3) mode of elicitation. 
Specification and ordering of questions 
As described above, to avoid respondent fatigue, progression of melanoma was simplified into 12 stages (and a 
death state): 3 in situ subtypes, and progressive from Stage 1a to 4 (as per American Joint Committee on Cancer 
[AJCC] definitions6).  The training session included an explanation to participants that if they felt there was a 
substantial difference in rate of progression from one stage to another by sub-type (e.g. Stage IIa superficial 
spreading vs Stage IIa lentigo maligna), then they should consider a weighted average risk based on their 
experience of case-mix.  Finally, to further minimise the impact of respondent fatigue, questions would be asked 
in random order. 
 Two further issues were the time horizon over which participants were asked to estimate changes and the 
number of patients in the cohort.  This was originally proposed to be 1000 patients over one month.  However, 
it was considered that insufficient patients would have progressed over this time, and that asking participants 
to allocate 1000 patients may lead to spurious precision.  Therefore, the time horizon was set at six months and 
participants were asked to allocate a cohort of 100 patients.   
Length of the webinar 
The webinar was originally proposed at three hours.  However, concerns were raised that it would be difficult 
to recruit participants for a three-hour session, and so the timing was reduced to two.  This proved to be a 
reasonable estimate in both piloting sessions. 
Mode of elicitation 
Two main modes of elicitation are the quantile and roulette modes.13  In the roulette mode, participants place 
‘chips in bins’ representing the relative strength of their belief about different values for a parameter.  Whilst 
commonly used to elicit binomial probabilities and continuous quantities, we considered this less suitable for 
eliciting multinomial probabilities.  Therefore, we opted for a quantile approach, where a minimum of 3 points 
along the distribution are elicited, typically the median and tertiles.  The tertile method was originally proposed: 
the median expressed as the value X at which the participant would place a 50:50 bet on the ‘true value’ being 
greater or less than X, and the lower and upper tertiles being the values at which a participant would place a 2:1 
bet.   
This was rejected by the steering group on the grounds that clinicians would not be familiar with tertiles and 
objections to the comparison with gambling to explain the method.  Despite the same rules of probability 
governing both clinical outcomes and games of chance, explanations in terms of betting odds were removed 
and tertiles (33% credibility intervals) rejected in favour of 95% credibility intervals, defined in terms of “it is 
possible for X to be greater than this value, but I would be extremely surprised if this were to be the case”.  The 
numeric quantity (1 in 40 or 2.5% probability) was also stated as the likelihood associated with this situation. 
Format of Results 
This manuscript is written to conform as closely as possible with recommendations for reporting of expert 
judgement,14  although this work was designed and conducted prior to publication of these guidelines.  We 
 report details of the participants, present tables and figures of aggregate distributions, and analysis of the 
feedback forms from participants, including time to complete. 
  
 Results 
Participants  
Sixteen participants agreed to take part in the exercise from a pool of 39 invited experts.  Of those, 13 
successfully completed the entire exercise, one completed questions on invasive disease only, and two did not 
complete any questions/withdrew their participation (Figure 2).  Elicitation from UK participants took place over 
four webinars scheduled between November 2015 and January 2016.  Elicitation from ANZ participants also took 
place over four webinars between January and February 2016. 
Elicited probabilities 
The results comprise a modified Connor-Mosimann (mCM) distribution for each question for each participant, 
plus a summary distribution representing the aggregation of all responses to each question (all UK, all ANZ and 
both combined).  Density plots proved somewhat unclear when visualising these data.  Therefore, we present 
box and whisker plots showing medians, interquartile and 100% ranges for the fitted distributions for UK and 
ANZ participants, and all combined (Figure 3).  Parameters of the respective mCM distributions and resulting 
medians and 95% credibility intervals (CrIs) for UK, ANZ and all combined are in Appendix 2. 
The broad rankings of disease progression are consistent between UK and ANZ, but there is some variation: in 
general, there was least disagreement in point-estimates (i.e. medians) for in situ and stage 1 disease.  There 
was most disagreement in medians for stages 2B, 2C and 4.  A crude mean of the credibility intervals for each 
stage suggests there is greatest overall uncertainty in progression from stages 3B, 3C and 4, and the least from 
in situ and stage 1B disease, although the 95% Credibility Interval varied between almost zero and one for the 
risk of remaining in an in situ stage.  These extremes are driven by the ANZ participants, with tighter 95%CrIs in 
the UK.  Finally, the results suggested a greater consensus in some of the transitions: regression of disease to an 
earlier stage was not generally considered possible (one of the ANZ participants believed there was a very small 
possibility for this), and progression straight to more extreme stages from in situ or early stage was considered 
less likely, with appropriately low medians and narrow 95% CrIs.   
Time to completion and analysis of feedback forms 
Time stamps reporting a time per question greater than 30 minutes were excluded (this was common for the 
first question asked where participants had opened the spreadsheet early.  Details of exclusions are in Appendix 
3).  After excluding these, the mean time to completion per question was 5m09sec (SD 3m16sec), with a total 
 time of 59m20sec (SD 21m19sec).  There was a downward trend with question number suggestive of either a 
learning effect and/or respondent fatigue (Figure 4).   
A summary of the feedback is in Table 2.  Four participants (29%) had heard of the concept of expert elicitation 
prior to this study with involvement in Delphi panels.  One participant had not taken part in one before but was 
familiar with the hierarchy of evidence and that sometimes expert opinion is the only source of relevant data.  
The mean (median) response to ease of understanding was 2.14 (2.00) on a 6-point scale, where 1=Easy and 
6=Difficult, with mean self-reported time to completion of 73.2 minutes (median 60).  This is slightly longer than 
the measured mean of 59m20sec.  However, the measured mean excludes outliers >30 minutes in length. 
Mean confidence in responses was 3.93 (median 4.00) on a six-point scale (1=Not at all confident, 6= very 
confident).  Free text explanations stated that whilst the answers may reflect a participant’s belief, the 
participant had concerns in the limitations of their beliefs due to lack of ‘hard’ evidence.  Other comments 
focused around the complexity of both melanoma as a disease, and of the staging recommendations.  The 
background of the participants was also mentioned, with dermatologists likely to be more confident in early 
stage progression and oncologists more familiar with later stage disease.  Due to small numbers we were unable 
to identify whether this was reflected in our data.  Finally, one respondent commented that the 6-month time 
horizon was too short and would have been more confident making a 1 or 2 year prognosis. 
Only 57% (8/14) participants felt this was a valid approach to answering the study question.  Some free text 
responses acknowledged that in the absence of ‘better’ evidence, expert elicitation was the only option.  Other 
participants suggested a cluster RCT of screening versus no-screening, or that the approach may be valid given 
a ‘large enough’ sample size (suggesting 100 respondents). 
All but two participants indicated they would be willing to take part in such an exercise again, although the 
participants are a self-selected group: a further two participants who initially agreed to take part declined to 
provide answers and did not provide feedback forms.  Most free-text comments suggested participants found it 
interesting with a desire to see the final results of the study.  
 Discussion 
Summary of results 
We elicited parametric distributions representing 12 unknown multinomial probabilities describing experts’ 
beliefs about the rate of progression of an individual with untreated melanoma from one stage to another over 
a 6-month time horizon.  The resulting distributions are in a format suitable for incorporation in a decision 
model.  The exercise revealed where there was varying confidence both within and between individuals in the 
rate of progression.  For example, the probability of progressing from 1A to 2C, 3A or 3B had medians of 1% to 
3%, with ‘tight’ 95%CrIs of 0% to 17%.  Other areas were highly uncertain: the 95%CrI of patient with in situ acral 
lentiginous melanoma remaining in that state ranges between 0% and 99%.  However, this is far from a uniform 
distribution (representing complete ignorance) as the median is 81%. 
Comparison with other studies 
Probably the most well-known structured elicitation technique is the SHELF tool (the SHeffield Elicitation 
Framework).13 15  This is a consensus-based approach requiring participants to agree on a final summary 
distribution representing their belief about plausible values for a single parameter.  Recently this has been 
extended to elicit multinomial parameters using a Dirichlet distribution.16  Our analysis here extends this by 
fitting elicited data to a Connor-Mosimann distribution10 11 modified to allow greater flexibility, thus providing a 
much better fit to the data.   
The SHELF approach, whilst considered best practice, suffers from several practical limitations.  Firstly, the 
consensus approach requires a face-to-face workshop bringing together all relevant participants into the same 
room at the same time.  As well as being somewhat logistically challenging, this approach limits the number of 
participants to 6-8 at most to facilitate conversation, and the workshop requires an experienced facilitator to 
ensure even representation of all views.  Finally, the consensus approach also limits the number of questions 
that can realistically be asked in one session to four or five at most. 
Other approaches have used computer-based methods.  For example, a study eliciting the opinion of nurses on 
the effectiveness of different bandages for severe pressure ulcers used a bespoke spreadsheet in Microsoft 
Excel/VBA.17  The nurses completed the task together in a computer suite, ensuring sufficient attention was paid 
to answering the questions as well as providing technical support in case of difficulties. 
 Previous decision modelling studies requiring an estimate of the risk of progression in undiagnosed and 
untreated melanoma18 19 had used notional 10% annual probabilities with a ‘wide’ 95%CrI of 0.0001% to 54.87% 
(a Beta(0.3,2.7) distribution).  This represents a mean of approximately 5.1% per 6-months.  The transition 
probabilities presented in this analysis are very different from these previous estimates.  It would be of value 
reiterating those previous models with these new parameter estimates to explore the impact on their 
conclusions. 
Practical issues associated with the elicitation protocol 
Piloting of the protocol was an extremely important component in this project, leading to several changes in 
approaches and indeed delayed the entire project by several months to ensure the internet-based workshop 
was as valuable as possible.  However, the rejection of tertiles in favour of 95% credible intervals may have 
resulted in loss of precision:  eliciting tertiles requires the participant to consider relative odds explicitly whereas 
eliciting 95% credibility intervals requires the participant to consider ‘almost certainty’, which is somewhat 
vague.  We also relied on verbal confirmation that experts had fully understood the nature of the task, were 
willing to honestly report their subjective uncertainty, and in particular understood the difference between 
means and medians.  Furthermore, in retrospect it may have been preferable to request estimates of prognosis 
over one- or two-year time horizon, not six months. 
Hosting the sessions as online webinars most likely increased the overall response rate, allowing scheduling to 
fit around the diaries of the participants.  However, we were only able to elicit responses from 14 participants 
(7 UK and 7 Aus/NZ) across eight facilitated sessions, although this may be a function of relative rarity of 
expertise in the area.  The numerous repeats of the webinar also required quite a number of input hours from 
the facilitator (EW), and a risk of inconsistency between webinars leading to systematically different results.  The 
effort could have been eased and consistency issues partially addressed by pre-recording the presentation 
component with subsequent opportunity for questions, although this reduces the interactivity of the session. 
We had originally intended to use a bespoke web-based tool for participants to record their answers.  This would 
be platform independent and automatically upload answers to a study database.  However, coding such a 
platform proved troublesome and we found it expedient to use a macro-enabled spreadsheet written in 
Microsoft Excel.  This led to its own problems, with participants requiring appropriate security settings on their 
 computers to allow macros to run.  In particular, the macros would only run on Windows PCs, not Macs.  
Participants with Macs therefore had to source Windows PCs in order to take part in the study. 
There was also a lack of clarity and apparent inconsistency between participants regarding the ‘dead’ state.  The 
intention of the facilitator was that this would be specifically melanoma-mortality as the decision model into 
which the results will be entered already includes background mortality.  However, this was not made explicit 
to the participants. Thus allowing a non-zero probability of death from an earlier stage implies that over that six 
months a participant believes that the patient could progress through all stages of the disease and die.  This is 
unlikely from Stage 1A, therefore the two participants that allowed non-zero values for death here may have 
been considering background mortality.  Making this explicit is a lesson for future studies of this nature.  
Justification for seeking expert opinion to inform parameter estimates 
The response of participants to the use of expert elicitation in decision making was very varied, ranging from 
complete acceptance to extreme scepticism, with only 57% considering this a valid approach.  It is therefore 
important to consider the alternative: decisions to adopt or reject new technologies must be made irrespective 
of the evidence available at the time.  A decision to remain with the status quo pending further evidence is still 
a decision not to adopt and so risks an opportunity loss.  The purpose of a decision model is to assemble all 
evidence there is, critically appraise it and structure it in a way to assist with a decision.  For example, short term 
effectiveness from an RCT combined with epidemiological data on long term progression.  There will always be 
gaps in this evidence, or areas where the ‘best available’ data may fall short of the ‘best conceivable’.  Decision 
modelling highlights this, and expert elicitation provides one means of plugging it where better quality evidence 
either does not yet exist or cannot exist/be collected (eg due to physical impossibility or ethical concerns as in 
the melanoma example presented here).  The alternative to this is subjective, informal discussion of decision 
makers.  A structured consultation process with relevant ‘experts’ focused on carefully eliciting their epistemic 
uncertainty may be considered superior a priori.  It should be noted that where data can be, and are, 
subsequently collected the model should be updated accordingly.  Where those data cannot be collected, the 
best that can be achieved is to present the results of the elicitation process fully and transparently, allowing 
readers to decide whether they feel the values are plausible.  If so, then all else being equal, the results 
generated from a decision model using those values must also be plausible. 
 Conclusion 
We successfully developed an online structured process that succeeded in eliciting and fitting a multinomial 
distribution, representing an aggregation of experts’ beliefs about the risk of progression of untreated 
melanoma from one stage to another.  The parameters of the overall distribution have been inserted into a 
decision model to estimate the cost-effectiveness of various screening and monitoring strategies to identify 
those at high risk of melanoma in a UK setting.5  Critically, the uncertainty in belief of experts about the rates of 
progression has been captured and when combined with uncertainty in other parameters, translated into 
decision uncertainty as to which strategies are likely to be the most cost-effective. 
  
 Table 1: Study questions 
In situ superficial spreading melanoma 
In situ lentigo maligna melanoma 
In situ acral lentiginous melanoma 
Stage Ia 
Stage Ib 
Stage IIa 
Stage IIb 
Stage IIc 
Stage IIIa 
Stage IIIb 
Stage IIIc 
Stage 4 
Participants were asked for their beliefs about the probability of progression from each of the 12 stages stated to any other 
stage and death. 
 
  
 Table 2: Summary of quantitative feedback from participants 
 Mean (SD)  
 Mean Median 
Had you heard of the concept of expert elicitation prior to this study? 29% Yes  
How easy or difficult did you find the concepts to understand? (1=Easy, 
6=difficult) 2.14 2.00 
How long did it take you to complete the questions (mins)? 73.21 60.00 
How confident are you that your answers reflect your belief about the 
risk of progression from one stage to another? (1=not at all confident, 
6=very confident) 3.93 4.00 
Do you think this is a valid approach to determining the risk of 
progression from one stage to another? 57% Yes  
Would you take part in one of these exercises again? 86% Yes  
 
 
  
 Figures 1a (left), b (mid) & c (right): Screenshots of Spreadsheet tool 
 
 
  
 Figure 2: Invitations and participants 
 
 
 
 
 
 
 
 
 
 
 
*6 provided full answers, 1 provided answers to questions on invasive disease stages only. 
  
24 15 Invited 
7* 
Backgrounds Consultant Dermatologist 
2x Consultant Oncologist 
Clinical researcher, Oncology 
Consultant Plastic Surgeon 
Medical Statistician, Cancer 
Senior Epidemiologist, Cancer 
 
2x Consultant Dermatologist 
2x Consultant Oncologist 
2x Senior Epidemiologist, Cancer 
Public health consultant 
 
7 Provided responses 
UK Aus/NZ 
Agreed to participate 9 7 
 Figures 3a&b: Summary results of UK, ANZ and both combined 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fitted modified Connor-Mosimann distributions for combined results of UK and ANZ participants and all 
combined.  Each row represents the starting stage.  Thus, the top left cell of Figure A2.1 shows the summary of 
all UK participants’ beliefs about the probabilities of a patient with in situ acral lentiginous melanoma (AL) 
transitioning to any other state after 6 months.  In this case, the median probability of remaining in the in situ AL 
stage is 82%, 6% probability of transitioning to stage 1A, 5% to 1B, 2% to 2A and 1% to stage 2B or death.  The 
IQRs (boxes) and ranges (whiskers) show the overall uncertainty in belief amongst the participants. 
AL: in situ acral lentiginous melanoma; LM: in situ lentigo maligna melanoma; SS: in situ superficial spreading 
melanoma; 1A – 4: invasive melanoma of stage 1A to 4 respectively; D: dead. 
  
 Figure 4: Time taken to respond to questions 
Points represent each participant’s response to each question.  Participants reporting more than 12 questions 
include repeated answers to previous questions.  Lines show fitted mean and associated 95% confidence interval.  
Note question number is the chronological order rather than a specific question: the order of questions was 
randomised. 
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 Appendix 1: Elicitation Protocol 
Background & Preparation 
A previously developed decision model19 is to be adapted to a new decision question to estimate the 
cost-effectiveness of a self-completed checklist as a potential screening tool for malignant melanoma.  
An input into this model is the risk of progression of malignant melanoma from one stage to the next 
in patients whose melanoma is undiagnosed and hence progresses without treatment.  For ethical 
reasons such data on the natural history of melanoma do not exist, although prognosis post diagnosis 
and treatment is well known.6  The original version of the model relied on a crude assumption with 
arbitrarily wide confidence interval to represent the uncertainty in risk of progression.  We wish to 
improve this for the revised model by conducting an elicitation exercise amongst group(s) of experts 
to elicit their opinion as to plausible risks. 
There are four main types of cutaneous melanoma (superficial spreading, lentigo maligna, acral 
lentiginous and nodular),7 which current guidelines categorise into nine stages of invasion.6  All but 
one are also described with a pre-invasive (in situ) phase; nodular melanoma is by definition invasive.  
We wish to elicit expert opinion on the rate of progression from each stage to any other. We have 
simplified a possible set of 39 questions into 12 by assuming that invasive disease would progress at 
the same rate irrespective of primary melanoma subtype; we allow the rate of progression from in 
situ disease to vary by subtype (Table A1).  Experts will be asked their opinions on the probability of 
moving from each of the twelve stages to any other (and death). 
Table A1: Stages for study questions 
In situ superficial spreading melanoma 
In situ lentigo maligna melanoma 
In situ acral lentiginous melanoma 
Stage Ia 
Stage Ib 
Stage IIa 
Stage IIb 
Stage IIc 
Stage IIIa 
Stage IIIb 
Stage IIIc 
Stage 4 
 
Identification and recruitment of experts 
Potential participants will be identified by two of the investigators (FW & JE), based on known 
expertise and relevant publications in the field.  They will be located in either the UK, Australia or New 
Zealand, and be of backgrounds including practicing and academic consultant dermatologists, 
oncologists, epidemiologists, plastic surgeons, and statisticians with a particular interest and expertise 
in melanoma. 
Experts will be invited to take part via letter emailed with a reply form (files 1 and 2) to enable 
scheduling of elicitation sessions.  These will be repeated according to availability of experts.  
Participants will be paid an honorarium of £200 / Aus$400 for their time.   
 Elicitation process 
Experts willing to take part in the process will be sent a welcome pack at least one week prior to their 
scheduled session.  This gives a brief introduction to the concepts of expert elicitation, introduction to 
the questions that will be asked of them, and relevant background materials (File 3 plus a copy of 
Balch et al. 20096).   
The process itself will take the form of a two-hour webinar comprising a 30-minute training session 
and 90 minutes to complete the exercise.  The presentation (file 4) covers the material provided in the 
welcome pack: an introduction to the concept of expert elicitation, details of the method used and 
examples, and a worked example of how to use the Excel spreadsheet to record responses.  The 
facilitator will then remain online over the next 90 minutes while participants complete the 
spreadsheet.  This is for two reasons: firstly, to resolve any issues or questions participants may have 
and secondly to encourage completion of the exercise in ‘real time’ and discourage rapid completion 
at a later date. 
Structuring 
All questions are of the format “Imagine a cohort of 100 patients with Stage X undiagnosed and hence 
untreated disease.  After six months, the patients may be in any of the following stages:”.  A bespoke 
Microsoft Excel spreadsheet was created to ask questions in turn and record responses (File 5).  The 
spreadsheet randomises the order of the questions to minimise any impact of respondent fatigue 
and/or learning effects. 
Experts are invited to select all possible stages from a drop-down list.  Once the possible stages are 
determined, experts rank them from most to least likely.  Clicking a button on the spreadsheet enters 
these stages into a chart.   
Experts assign probabilities using the quantile method, where median and upper and lower 95% 
credible limits are elicited: 
Starting with the least likely stage (i.e. working from the right-hand side of the chart), the expert 
adjusts a slider (or simply enters a number into the table below) representing their median belief 
about the number of patients expected to be in that stage after 6 months.  They then move on to the 
next least likely and assign their median beliefs.  The expert repeats this until the medians have been 
entered for all possible stages.  The sum of the medians must equal 100: all 100 patients must be 
assigned to a state.  The chart gives instant visual feedback to the expert who adjusts the medians 
until he/she is satisfied that his/her median beliefs are adequately represented. 
The expert now assigns the lower and upper 95% credible limits to their beliefs.  Again, commencing 
with the least likely stage the expert enters the relevant numbers.  Numerically, the experts should 
set the limits such that they believe there is a 1 in 20 chance that the ‘true values’ would be outside 
the range, that is a 1 in 40 chance of exceeding the upper limit and a 1 in 40 chance of deceeding the 
lower limit.  However, this is explained to the experts in the training that it should represent a value 
where the expert ‘believes it is possible to be outside this range, but would be extremely surprised if 
that turned out to be the case’.  Other approaches were considered, for example eliciting tertiles (33% 
credibility intervals), but following piloting, 95% credibility intervals were considered the least taxing 
method due to general familiarity with 95% confidence intervals. 
 Once the expert is happy with his/her response, he/she presses the ‘submit’ button.  This timestamps 
and records the data within the Excel workbook, saves the spreadsheet on the participant’s hard drive 
and moves on to the next question. 
Once all questions are completed, the expert is offered the opportunity to repeat any of the questions.  
If not, the expert is asked to email the spreadsheet back to the facilitator and complete a feedback 
form (file 6). 
Fitting distributions to elicited beliefs 
A modified Connor-Mosimann (mCM) distribution9 16 will be fitted to the elicited quantities from each 
expert.  The mCM is a generalisation of the Connor-Mosimann distribution, itself a generalisation of 
the Dirichlet distribution, which defines a multinomial distribution.  The advantage of the 
generalisations is the added flexibility to provide a better fit to elicited quantities.  Wilson9 provides R 
code10 to fit the mCM distribution.  This code will be used to fit the multinomial distribution to each 
expert’s response to each question.  To generate an aggregate distribution representing the spread of 
beliefs of all experts, these distributions will be sampled from many times, and the median and 95% 
credibility limits calculated.  The combined mCM will then be fitted to these quantities. 
 
 
  
 Appendix 2: Parameters of mCM distributions 
   
Parameters of mCM distribution 
Associated medians, upper and 
lower 95% credibility limits 
Experts From To a b L U LL MEDIAN UL 
ANZ AL AL 0.59743 0.304534 0 0.999995 0.01 0.79 1.00 
1A 9.631271 6.309027 0.221636 0.99999 0.00 0.14 0.75 
1B 2.311285 0.977214 1.00E-05 0.937206 0.00 0.03 0.29 
2A 2.983218 0.268063 0.016502 0.488581 0.00 0.01 0.08 
2B 0.487804 9.39963 0.554548 0.806302 0.00 0.00 0.06 
2C 10 8.041188 0.542353 0.771784 0.00 0.00 0.03 
3A 9.127489 0 1.00E-05 0.613719 0.00 0.00 0.01 
3B 0 0 0 0 0.00 0.00 0.01 
LM LM 0.283675 0.131301 0.018904 0.997543 0.02 0.93 1.00 
1A 8.204178 2.194021 0.359029 0.989642 0.00 0.06 0.90 
1B 8.714595 9.670652 0.017422 0.993675 0.00 0.00 0.12 
3A 9.34394 2.577571 0.579118 0.745076 0.00 0.00 0.09 
2A 0.478753 8.624764 0.901361 0.982634 0.00 0.00 0.03 
2B 8.549465 8.683784 0.062673 0.22357 0.00 0.00 0.00 
2C 0 0 0 0 0.00 0.00 0.00 
SS SS 0.030154 0.02798 0.028879 0.99999 0.03 0.81 1.00 
1A 10 9.000856 0.496504 0.988517 0.00 0.15 0.82 
1B 10 9.812086 1.00E-05 0.983211 0.00 0.02 0.18 
2A 10 7.72739 0.010062 0.989516 0.00 0.01 0.11 
2B 9.913193 0 0.318397 0.364845 0.00 0.00 0.03 
2C 9.904355 9.93199 0.009053 0.06772 0.00 0.00 0.00 
3A 0 0 0 0 0.00 0.01 0.06 
1A 1A 1.504461 0.667352 0 1 0.12 0.76 1.00 
1B 10 10 0 0.945677 0.00 0.11 0.45 
2A 0 10 0.439209 0.99999 0.00 0.06 0.22 
2B 0 0 1.00E-05 0.99999 0.00 0.00 0.25 
3A 10 10 1.00E-05 0.99999 0.00 0.00 0.13 
2C 1.487797 10 0.81765 1 0.00 0.00 0.11 
3B 0 0 0 1 0.00 0.00 0.02 
3C 10 0 1.00E-05 0.99999 0.00 0.00 0.02 
4 0 10 0.99999 1 0.00 0.00 0.00 
Death 0 0 0 1 0.00 0.00 0.00 
SS 0 0 0 0 0.00 0.00 0.00 
1B 1B 0.102911 0.090419 0.059234 0.936614 0.06 0.65 0.94 
2A 7.176432 8.869692 1.00E-05 0.968591 0.02 0.14 0.57 
2B 8.336562 8.602221 0.117337 0.880202 0.01 0.09 0.38 
3B 9.820876 1.205356 0.053221 0.077521 0.00 0.01 0.03 
3A 8.884178 8.545433 0.091749 0.382907 0.00 0.02 0.09 
2C 2.75241 1.327872 0.801846 0.827324 0.01 0.05 0.22 
3C 0 7.331239 0.136902 0.949866 0.00 0.00 0.01 
4 1.98482 0.072729 0.054859 0.897669 0.00 0.01 0.04 
Death 8.294663 9.220662 0.008618 0.781475 0.00 0.00 0.00 
 1A 0 0 0 0 0.00 0.00 0.00 
2A 2A 1.951325 1.017888 0.009653 0.968314 0.15 0.68 0.96 
2B 4.140928 2.445235 0 1 0.03 0.19 0.61 
3A 0.622836 9.76566 0.341722 0.935004 0.00 0.04 0.17 
2C 1.553755 0.320453 0.018295 0.733605 0.00 0.04 0.18 
3B 4.479816 0 0.168717 0.344376 0.00 0.01 0.04 
4 10 8.088065 0.710776 0.895263 0.00 0.01 0.07 
3C 2.524135 10 1.00E-05 0.814571 0.00 0.00 0.00 
Death 0 0 0 0 0.00 0.00 0.01 
2B 2B 0.248326 0.207882 0.002298 0.997483 0.00 0.62 1.00 
2C 0.620873 0.470587 0.004969 0.99472 0.00 0.10 0.97 
3A 1.006865 1.779137 0.008102 0.99712 0.00 0.01 0.48 
3B 2.864799 3.488157 0.006589 0.998085 0.00 0.01 0.35 
4 1.162021 2.386737 0.005065 0.99534 0.00 0.00 0.17 
Death 0.483908 1.378194 0.004843 0.992812 0.00 0.00 0.10 
3C 1.975598 0.544843 0.012471 0.99692 0.00 0.00 0.19 
2A 0 0 0 0 0.00 0.00 0.06 
2C 2C 0.397347 0.355192 0.076073 0.894542 0.08 0.53 0.89 
3B 0 0 0.06112 0.939323 0.01 0.06 0.87 
3A 1.409543 1.820839 0.095126 0.822627 0.00 0.03 0.50 
3C 1.440143 1.137282 0.229924 0.841103 0.00 0.02 0.41 
4 2.898793 0.574577 0.099681 0.848899 0.00 0.01 0.24 
Death 2.482492 1.133833 0.117518 0.918665 0.00 0.00 0.07 
2B 0 0 0 0 0.00 0.00 0.04 
3A 3A 2.995168 1.930706 0.006841 0.994313 0.21 0.63 0.93 
3B 1.27867 1.159076 0.015874 0.990167 0.01 0.17 0.58 
3C 1.906755 2.013663 0.025001 0.976564 0.00 0.06 0.33 
4 2.31061 1.267642 0.025228 0.978739 0.00 0.04 0.24 
Death 1.358594 0.311688 0.038384 0.977857 0.00 0.01 0.13 
1A 0.430853 0.923095 0.02233 0.984153 0.00 0.00 0.02 
1B 1.066876 1.622707 0.017447 0.95757 0.00 0.00 0.01 
2A 5.490861 1.836449 0.032182 0.973223 0.00 0.00 0.02 
2B 2.352341 2.808732 0.021257 0.951185 0.00 0.00 0.00 
2C 0 0 0 0 0.00 0.00 0.00 
3B 3B 3.175643 2.840464 0 1 0.17 0.53 0.87 
3C 2.283026 1.809225 0 1 0.04 0.24 0.62 
4 0.764168 0.177426 0 1 0.01 0.14 0.50 
Death 0 0 0 0 0.00 0.00 0.27 
3C 3C 2.358183 1.996845 0.199707 1 0.30 0.64 0.94 
4 9.774438 2.525477 0.103695 1 0.05 0.29 0.60 
Death 0 0 0 0 0.01 0.06 0.20 
4 4 2.509242 0.853222 0.067355 1 0.30 0.81 1.00 
Death 0 0 0 0 0.00 0.19 0.70 
UK AL AL 0.369688 0.229379 0.3855 0.959007 0.39 0.82 0.96 
1A 9.598789 4.070474 1.00E-05 0.99999 0.02 0.12 0.50 
1B 2.492956 0 0.432166 0.451401 0.00 0.02 0.12 
2A 8.435852 1.683278 0 0.537005 0.00 0.01 0.07 
2B 10 4.326686 0 0.297963 0.00 0.00 0.02 
 2C 4.741977 8.422931 0.99999 1 0.00 0.01 0.07 
Death 0 0 0 0 0.00 0.00 0.00 
LM LM 2.301555 0.558191 0.00289 0.998852 0.29 0.88 1.00 
1A 2.62531 1.557074 0.020133 0.994679 0.00 0.07 0.51 
1B 4.816311 9.578459 0.017625 0.974256 0.00 0.01 0.12 
2A 9.505588 9.616541 0.005425 0.97701 0.00 0.01 0.12 
2B 9.897045 5.116054 0.006307 0.992072 0.00 0.01 0.08 
Death 0 0 0 0 0.00 0.00 0.04 
SS SS 3.279439 0.882013 0.022255 0.99999 0.37 0.84 1.00 
1A 2.12226 0.230381 0.01257 0.822724 0.00 0.12 0.49 
1B 10 1.000246 1.00E-05 0.578567 0.00 0.02 0.11 
2A 3.886608 0.829852 1.00E-05 0.880147 0.00 0.01 0.07 
2C 0 10 0.394195 1 0.00 0.00 0.01 
Death 0 0 0 0 0.00 0.00 0.02 
1A 1A 0.174328 0.146953 0 1 0.00 0.65 1.00 
1B 0 10 0.546081 1 0.00 0.19 0.55 
2A 2.360595 10 0 0.775024 0.00 0.02 0.13 
2B 0 0 0 0.635571 0.00 0.00 0.27 
3A 0.564205 4.175201 1.00E-05 0.99999 0.00 0.00 0.11 
3B 10 10 0.73863 1 0.00 0.05 0.35 
2C 10 10 0.144976 1 0.00 0.00 0.03 
3C 10 10 0.030998 0.706957 0.00 0.00 0.01 
4 0 10 0 1 0.00 0.00 0.00 
Death 0 0 0 0 0.00 0.00 0.02 
1B 1B 0.223691 0.182173 0.171267 0.920287 0.17 0.71 0.92 
2A 7.92191 3.742915 0 0.472585 0.02 0.09 0.33 
2B 6.852427 5.311878 0.188886 0.364835 0.01 0.06 0.19 
2C 3.170922 3.883282 0.013786 0.625196 0.01 0.04 0.18 
3A 0 8.025806 0.563521 0.708222 0.01 0.05 0.20 
3B 3.350625 8.537315 0.106292 0.129229 0.00 0.00 0.02 
3C 7.109377 4.703316 0.16711 0.865774 0.00 0.02 0.09 
Death 3.219595 3.193568 0.357788 1 0.00 0.01 0.05 
4 0 0 0 0 0.00 0.00 0.03 
2A 2A 0.659129 0.447355 0.010228 0.861544 0.02 0.58 0.86 
2B 1.436617 3.423216 0.215948 1 0.04 0.18 0.59 
2C 5.873514 2.755437 1.00E-05 0.496491 0.01 0.07 0.25 
3A 8.252809 0 1.00E-05 0.493687 0.02 0.07 0.22 
3B 0 0 0.067978 0.735867 0.00 0.01 0.15 
4 7.87938 10 1.00E-05 0.657204 0.00 0.01 0.06 
3C 10 3.688372 0 1 0.00 0.02 0.11 
Death 0 0 0 0 0.00 0.01 0.04 
2B 2B 1.534297 2.030859 0.00039 0.999846 0.05 0.42 0.88 
2C 2.097513 8.208028 0.169449 0.998589 0.04 0.18 0.42 
3A 0.817723 0.97243 1.00E-05 0.999088 0.00 0.14 0.52 
3B 0.896715 0 0.003156 0.494168 0.00 0.09 0.27 
3C 0.012378 0.004207 0.003793 0.999202 0.00 0.05 0.27 
4 9.980448 0.012976 0.999302 0.99999 0.00 0.00 0.22 
Death 0 0 0 0 0.00 0.00 0.00 
 2C 2C 2.507996 4.105559 0.006301 0.991172 0.09 0.37 0.74 
3B 1.289735 3.476961 1.00E-05 0.977609 0.01 0.14 0.48 
3C 1.095318 2.461759 1.00E-05 0.99999 0.01 0.11 0.44 
3A 9.937615 4.300662 0.022216 0.98025 0.04 0.20 0.48 
4 0.130387 0.030762 0 0.967015 0.00 0.07 0.24 
Death 0 0 0 0 0.00 0.00 0.16 
3A 3A 1.071636 0.966509 0.005961 0.985589 0.04 0.53 0.97 
3B 2.55411 3.56696 0.006701 0.983128 0.01 0.16 0.57 
3C 0.285266 0.255283 0.010596 0.998774 0.00 0.08 0.58 
4 4.801688 2.091451 0.016015 0.993641 0.00 0.04 0.41 
Death 0 0 0 0 0.00 0.01 0.21 
3B 3C 2.969611 4.448676 0.002981 0.933115 0.10 0.37 0.69 
3B 0.349255 0.45477 0.292156 0.946387 0.12 0.31 0.75 
4 8.199244 4.628028 0.086768 1 0.02 0.17 0.42 
Death 0 0 0 0 0.01 0.07 0.25 
3C 3C 3.290765 4.27166 0.096936 0.933029 0.21 0.45 0.74 
4 4.453119 1.807437 0.010596 0.983427 0.14 0.37 0.65 
Death 0 0 0 0 0.03 0.14 0.40 
4 4 5.276575 4.389197 0.002909 0.99769 0.24 0.55 0.83 
Death 0 0 0 0 0.17 0.45 0.76 
ALL AL AL 0.839126 0.385843 1.00E-05 0.99999 0.03 0.79 1.00 
1A 1.492014 0.247581 0 0.759439 0.00 0.13 0.70 
1B 10 10 0 0.969459 0.00 0.03 0.23 
2A 6.602994 8.077545 1.00E-05 0.776528 0.00 0.01 0.09 
2B 8.717574 9.295483 0 0.671483 0.00 0.01 0.05 
2C 9.633907 10 0.246869 0.810438 0.00 0.01 0.06 
3A 8.704724 9.195737 0 0.972577 0.00 0.00 0.02 
3B 0.708039 10 0.086467 1 0.00 0.00 0.00 
Death 0 0 0 0 0.00 0.00 0.02 
LM LM 0.167053 0.10176 0.022832 0.999198 0.02 0.92 1.00 
1A 9.623585 2.133245 0.07268 0.955987 0.00 0.06 0.88 
1B 9.884843 9.987646 0.038889 0.604451 0.00 0.00 0.11 
3A 2.411535 9.960102 0.100902 0.994081 0.00 0.00 0.07 
2A 9.963524 3.22278 0.01894 0.664518 0.00 0.00 0.09 
2B 9.810062 9.969743 0.649155 0.964291 0.00 0.00 0.07 
2C 8.907087 8.113418 0.958967 0.987231 0.00 0.00 0.02 
Death 0 0 0 0 0.00 0.00 0.00 
SS SS 0.739052 0.319184 0.002824 0.995898 0.03 0.83 1.00 
1A 2.068897 2.033196 0.610485 1 0.00 0.14 0.82 
1B 9.054651 6.031458 0.011876 0.973273 0.00 0.02 0.15 
2A 9.687131 2.788773 0.033901 0.902645 0.00 0.01 0.08 
2B 7.133308 9.546354 0.264258 0.989727 0.00 0.00 0.02 
2C 0.44956 0.136839 0.038445 0.621446 0.00 0.00 0.01 
3A 9.631037 0.264069 0.004024 1 0.00 0.00 0.01 
Death 0 0 0 0 0.00 0.00 0.00 
1A 1A 1.034381 0.568252 1.00E-05 0.99999 0.05 0.72 1.00 
1B 9.733502 9.973478 0.004373 1 0.00 0.14 0.53 
2A 2.931828 9.951031 0.001945 1 0.00 0.03 0.16 
 2B 0.051924 0.232846 0.009194 0.984818 0.00 0.00 0.26 
3A 9.86484 9.992441 1.00E-05 0.365153 0.00 0.01 0.08 
2C 0.010515 0.125603 0.030811 0.989357 0.00 0.00 0.10 
3B 9.867243 9.902834 0.02078 0.993498 0.00 0.02 0.17 
3C 0 9.994807 0.013573 0.961755 0.00 0.00 0.00 
4 0 9.971261 0.009402 0.99999 0.00 0.00 0.00 
Death 0.160857 10 0 0.991819 0.00 0.00 0.01 
SS 0 0 0 0 0.00 0.02 0.16 
1B 1B 0.448233 0.294108 0.098371 0.923842 0.10 0.69 0.92 
2A 10 9.914674 0 0.957017 0.03 0.14 0.52 
2B 0.892612 1.658899 1.00E-05 0.962568 0.00 0.03 0.33 
2C 0 9.695914 0.392525 0.909939 0.00 0.03 0.18 
3A 0.232188 0.398362 1.00E-05 0.939368 0.00 0.01 0.18 
3B 9.841029 9.398021 0 0.93445 0.00 0.01 0.12 
3C 9.525846 9.76894 0.064622 0.967901 0.00 0.01 0.07 
4 9.808781 0.844963 0.081298 0.931483 0.00 0.01 0.06 
Death 0.787374 10 0.965123 0.99999 0.00 0.00 0.01 
1A 0 0 0 0 0.00 0.00 0.00 
2A 2A 1.687969 1.004313 1.00E-05 0.91826 0.11 0.61 0.91 
2B 2.725174 2.357424 0.02302 0.962066 0.03 0.18 0.60 
3A 8.994734 9.106172 0 0.628603 0.01 0.05 0.19 
2C 0.523682 0.622619 0.219633 0.883525 0.01 0.05 0.25 
3B 5.261794 8.58761 0.265845 0.691082 0.00 0.02 0.10 
4 0.077742 1.900017 0.469569 0.81829 0.00 0.01 0.07 
3C 9.482078 2.686904 0.658586 0.739639 0.00 0.01 0.05 
Death 0 0 0 0 0.00 0.00 0.02 
2B 2B 0.259866 0.257236 0.009117 0.994492 0.01 0.52 0.99 
2C 4.960413 10 0.007869 0.986863 0.00 0.14 0.49 
3A 2.068522 2.495441 0.027659 0.977224 0.00 0.11 0.52 
3B 4.565419 5.172593 0.019409 0.991251 0.00 0.06 0.31 
3C 0.139852 0.23038 0.009796 0.990614 0.00 0.00 0.24 
4 0.387311 0.262258 0.009867 0.984233 0.00 0.00 0.21 
Death 6.786227 8.605502 0.00828 0.981074 0.00 0.00 0.08 
2A 0 0 0 0 0.00 0.00 0.11 
2C 2C 1.977441 2.396082 0.014196 0.953622 0.09 0.44 0.83 
3B 0.129428 0.174102 0.057696 0.98636 0.01 0.14 0.82 
3A 1.036033 1.319266 0 0.942916 0.00 0.07 0.52 
3C 1.813304 1.456001 0.030214 0.931945 0.00 0.05 0.41 
4 4.445778 1.758624 0.061265 0.927437 0.00 0.03 0.26 
Death 4.173727 1.342888 0.074551 0.922388 0.00 0.01 0.10 
2B 0 0 0 0 0.00 0.00 0.04 
3A 3A 1.392516 0.992749 0.012544 0.976772 0.08 0.61 0.96 
3B 1.36006 1.643439 0.014562 0.986543 0.01 0.15 0.63 
3C 0.983344 0.586824 0.010825 1 0.00 0.09 0.54 
4 1.690844 0.340197 0.012112 0.991131 0.00 0.03 0.35 
Death 0.437478 0.071505 0.026964 0.992584 0.00 0.00 0.10 
1A 0.034552 0.218092 0.021633 0.993463 0.00 0.00 0.00 
1B 4.673151 0.697417 0.020752 0.968636 0.00 0.00 0.01 
 2A 0.032524 0.32729 0.007318 0.989644 0.00 0.00 0.00 
2B 0.05443 0.035732 0.014095 0.992498 0.00 0.00 0.00 
2C 0 0 0 0 0.00 0.00 0.00 
3B 3B 1.25305 2.102565 0.12553 0.994641 0.15 0.43 0.87 
3C 2.722162 1.931761 0.003412 0.99726 0.05 0.30 0.68 
4 2.21584 1.484447 0.339041 0.996612 0.02 0.14 0.44 
Death 0 0 0 0 0.00 0.04 0.21 
3C 3C 3.785295 2.926405 0.007746 0.988342 0.21 0.57 0.87 
4 4.02447 1.405257 0 1 0.08 0.31 0.66 
Death 0 0 0 0 0.01 0.09 0.36 
4 4 1.841319 1.456665 0.170922 0.99999 0.26 0.64 0.96 
Death 0 0 0 0 0.04 0.36 0.74 
 
Medians do not sum to 100% due to rounding. AL = in situ acral lentiginous melanoma; LM = in situ lentigo 
maligna melanoma SS = in situ superficial spreading melanoma 
  
 Appendix 3: Excluded data from time to completion analysis 
Of 14 respondents, 7 reported a time to completion of the first question of greater than 30 minutes.  
We assumed these were due to respondents opening the spreadsheet prior to commencement of the 
exercise.  Two respondents also reported time stamps of 13 and 19 hours, and one of these 
respondents subsequently reported a time of 1hr8mins for one question.  The 13 and 19 hours were 
cases where respondents had requested adjournment and completion of the exercise the following 
day.  The reason for the 1h08 time over one question is unknown, but is consistent with a break from 
the exercise (it was on the third question following overnight adjournment). 
 
 
